EDIT Latest News

Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference

globenewswire.com — Mar 27, 2026

CAMBRIDGE, Mass. , March 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc.

Editas Medicine, Inc. (NASDAQ:EDIT) Receives Consensus Rating of “Moderate Buy” from Analysts

defenseworld.net — Mar 19, 2026

Shares of Editas Medicine, Inc. (NASDAQ: EDIT - Get Free Report) have been given a consensus rating of "Moderate Buy" by the eight analysts that are

Is Editas Medicine Going to $0?

fool.com — Mar 17, 2026

Editas Medicine has been on fire over the trailing-12-month period. However, the stock has been crushed since 2021, as it has faced plenty of setback

Editas Medicine, Inc. (EDIT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

seekingalpha.com — Mar 12, 2026

Editas Medicine, Inc.

EDIT Stock Up on Narrower-Than-Expected Q4 Loss, Revenues Rise Y/Y

zacks.com — Mar 10, 2026

Editas stock jumps 16% on reporting a narrower-than-expected Q4 loss and beating revenue estimates while advancing its EDIT-401 gene-editing candidate